EXAS insider sale: 2,858 shares at $70.08 by EVP under plan

Rhea-AI Filing Summary

Exact Sciences (EXAS) reported an insider transaction by EVP, GM, Precision Oncology Brian Baranick. He sold 2,858 shares of common stock on 11/04/2025 at $70.08 per share, executed pursuant to a Rule 10b5-1 trading plan entered into on May 13, 2024.

Following the sale, he beneficially owned 22,368 shares directly and 670 shares held in a 401(k) plan. In addition, he holds an aggregate of 73,080 vested and unvested options and restricted stock units, with each RSU representing a contingent right to receive one share of common stock.

Insights

Insider transactions analyst

Planned insider sale; routine, limited informational impact.

An executive sold 2,858 EXAS shares at $70.08 on 11/04/2025 under a pre-arranged Rule 10b5-1 plan dated May 13, 2024. Such plans automate trades to reduce discretion and potential timing concerns.

Post-transaction direct holdings are 22,368 shares, plus 670 shares in a 401(k). The filing notes 73,080 combined options and RSUs outstanding, which are baseline equity awards and not part of this sale.

Overall, this is an administrative disclosure of a modest, scheduled sale. Actual market impact depends on future filings disclosing any additional transactions or changes.

Insider Trade Summary

Net Seller: 2,858 shares ($200,289)

Net Sell 2 txns

Insider Baranick Brian

Role EVP, GM, Precision Oncology

Sold 2,858 shs ($200K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,858	$70.08	$200K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 22,368 shares (Direct); Common Stock — 670 shares (Indirect, Held in 401(k) Plan)

Footnotes (1)

1. The transaction reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into on May 13, 2024. In addition to the shares of Common Stock reported on this Form 4, which total 23,038 shares, Mr. Baranick also holds, in the aggregate, an additional 73,080 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baranick Brian

(Last) (First) (Middle)

C/O EXACT SCIENCES CORP.

5505 ENDEAVOR LANE

(Street)

MADISON WI 53719

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EXACT SCIENCES CORP [ EXAS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, GM, Precision Oncology

3. Date of Earliest Transaction (Month/Day/Year)
11/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/04/2025		S		2,858(1)	D	$70.08	22,368(2)	D
Common Stock								670	I	Held in 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transaction reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into on May 13, 2024.

2. In addition to the shares of Common Stock reported on this Form 4, which total 23,038 shares, Mr. Baranick also holds, in the aggregate, an additional 73,080 vested and unvested options to purchase shares of Common Stock and restricted stock units, with each restricted stock unit representing a contingent right to receive one share of Common Stock.

	/s/ Brian Baranick by Mark Busch, attorney-in-fact	11/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did EXACT SCIENCES (EXAS) disclose in this Form 4?

EVP Brian Baranick sold 2,858 shares on 11/04/2025 at $70.08 per share under a Rule 10b5-1 plan.

Was the EXAS insider transaction under a Rule 10b5-1 plan?

Yes. The sale was executed pursuant to a Rule 10b5-1 trading plan entered into on May 13, 2024.

How many EXAS shares does the insider hold after the sale?

He beneficially owned 22,368 shares directly and 670 shares in a 401(k) plan after the sale.

What price and amount were involved in the EXAS insider sale?

The insider sold 2,858 shares at a price of $70.08 per share.

Does the insider have additional EXAS equity awards?

Yes. He holds an aggregate of 73,080 vested and unvested options and RSUs (each RSU for one share).

What is the insider’s role at Exact Sciences (EXAS)?

He is an Officer, serving as EVP, GM, Precision Oncology.